NeuroPace Inc(NPCE)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

NeuroPace Inc (NPCE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NPCE at 32.4/100 on a 32-signal composite quality model, placing it at rank #2,429 of 2,961 stocks — the bottom half of the AI-ranked universe. NPCE scores in the top quartile across revenue growth (80.8). Areas of concern include balance sheet strength (11.6) and free cash flow (16.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 15.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), NeuroPace Inc reports quarterly revenue of $22.8M, net income of $-6.2M, an operating margin of -22.5%. Top institutional holders of NPCE by reported 13-F value include Polar Capital Plc, Soleus Capital Management, L.P., First Light Asset Management, based on the most recent SEC filings. NPCE trades on the Nasdaq exchange and files with the SEC under CIK 1528287. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NPCE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NeuroPace Inc directly from SEC EDGAR.